Benitec Biopharma Reports Increased Quarterly Loss Amid Rising Expenses
Benitec Biopharma reported a Q1 net loss of $8.965 million, up from $5.059 million the previous year, due to increased operating expenses of $9.803 million. Despite the losses, the company holds $94.5 million in cash and remains focused on advancing clinical trials and exploring collaborations.
Benitec Biopharma ( (BNTC) ) has released its Q1 earnings. Here is a breakdown of the information Benitec Biopharma presented to its investors.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Benitec Biopharma Inc. is a biotechnology company specializing in the development of genetic medicines using its proprietary ‘Silence and Replace’ DNA-directed RNA interference platform, which combines RNA interference with gene therapy to target disease-causing genes. In its recent earnings report for the quarter ending September 30, 2025, Benitec Biopharma reported a net loss of $8.965 million, an increase from the $5.059 million loss in the same quarter of the previous year. The company’s operating expenses rose significantly to $9.803 million, driven by increased general and administrative costs. Despite the losses, the company maintains a strong cash position with $94.5 million in cash and cash equivalents, providing a buffer for ongoing research and development activities. Looking ahead, Benitec Biopharma remains focused on advancing its product candidates through clinical trials and exploring potential collaborations and out-licensing opportunities to support its strategic goals.
